AR and prostate carcinoma: Since androgen receptor (AR) plays a critical role in the development and progression of prostate cancer, androgen deprivation therapy (ADT) with lowering of serum testosterone levels to castrate levels has been the mainstay of therapy for these patients for years 44-47.